Revolution Medicines wins FDA approval for Rasonque, the first drug to target the genetic driver of pancreatic cancer
The US Food and Drug Administration has approved Revolution Medicines' daraxonrasib, to be sold as Rasonque, for adults with previously treated metastatic pancreatic cancer — a landmark, because it is the first medicine cleared to attack RAS, the faulty protein that drives most pancreatic tumours and had long been considered "undruggable".
Pancreatic cancer is one of the deadliest common cancers: because it is usually caught late, most patients live well under a year once first-line chemotherapy stops working. Rasonque is a once-daily pill that switches off RAS signalling — the internal "on switch" that tells tumour cells to keep growing — across a broad range of the genetic variants seen in these tumours.
The approval rests on the Phase 3 RASolute 302 trial (500 patients), whose results were published in the New England Journal of Medicine. Patients on Rasonque lived a median of 13.2 months versus 6.7 months on chemotherapy — roughly a doubling of survival — and their risk of death fell by 60% (hazard ratio 0.40). More than half were still alive at one year, against fewer than one in five on chemotherapy. Time before the disease worsened also roughly doubled, from 3.6 to 7.2 months.
Revolution Medicines is also testing daraxonrasib as an earlier, first-line pancreatic cancer treatment and in other RAS-driven cancers such as lung and colorectal, positioning RAS-targeting as a potential new backbone of cancer therapy.
Source: STAT News, 26 August 2026; RASolute 302 data New England Journal of Medicine.